European Journal of Cancer
Volume 45, Issue 1 , Pages 90-98 , January 2009

Management and outcome of stage 3 neuroblastoma

  • Shakeel Modak

      Affiliations

    • Department of Paediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
    • Corresponding Author InformationCorresponding author: Tel.: +1 212 639 7623; fax: +1 212 717 3695.
    • ,
  • Brian H. Kushner

      Affiliations

    • Department of Paediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
    • Tel.: +1 212 639 6793
    • ,
  • Michael P. LaQuaglia

      Affiliations

    • Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
    • Tel.: +1 212 639 7002
    • ,
  • Kim Kramer

      Affiliations

    • Department of Paediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
    • Tel.: +1 212 639 6410
    • ,
  • Nai-Kong V. Cheung

      Affiliations

    • Department of Paediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
    • Tel.: +1 646 888 2313

Received 17 July 2008 ,Revised 24 August 2008 ,Accepted 25 September 2008.

References 

  1. Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993;11:1466–1477
  2. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 933–70.
  3. Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumour cell ploidy. J Clin Oncol. 2005;23:8819–8827
  4. Rubie H, Hartmann O, Michon J, et al. N-myc gene amplification is a major prognostic factor in localized neuroblastoma: results of a french NBL study. J Clin Oncol. 1997;15:1171–1182
  5. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24:2891–2896
  6. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649–658
  7. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. New Engl J Med. 1999;341:1165–1173
  8. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a children’s cancer group study. J Clin Oncol. 1998;16:1256–1264
  9. Cheung NKV, Kushner BH, LaQuaglia MP, et al. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biologic markers. Eur J Cancer. 1997;33:2117–2121
  10. Kushner BH, Cheung NK, LaQuaglia MP, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol. 1996;14:373–381
  11. Cecchetto G, Mosseri V, De Bernardi B, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group. J Clin Oncol. 2005;23:8483–8489
  12. Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: results of the GPOH NB97 trial. Pediatr Blood Cancer. 2008;50:965–969
  13. Cheung NK, Kushner BH, LaQuaglia M, et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001;36:227–230
  14. Kushner BH, Kramer K, Cheung NKV. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19:4189–4194
  15. 15 Kreissman SG, Villablanca JG, Diller L, et al. Response and toxicity to a dose-intensive multi-agent chemotherapy induction for high-risk neuroblastoma: a Children’s Oncology Group (COG A3973) study. J Clin Oncol. 2007;25:9505
  16. Garaventa A, Boni L, Lo Piccolo MS, et al. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol. 2002;13:956–964
  17. Laverdiere C, Cheung NK, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer. 2005;45:324–332
  18. De Bernardi B, Conte M, Mancini A, et al. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol. 1995;13:884–893
  19. 19 Kushner BH, LaQuaglia MP, Ambros PF, et al. Survival from locally invasive or metastatic neuroblastoma (NB) without cytotoxic therapy (Rx). Proc Am Soc Clin Oncol. 1993;12:413
  20. Park JE, London W, Maris JM, et al. Prognostic markers for stage 3 neuroblastoma (NB): a report from the International Neuroblastoma Risk Group (INRG) project. Proc ASCO. 2008;
  21. Baker DL, Schmidt M, Cohn SL, et al. A phase III trial of biologically-based therapy reduction for intermediate risk neuroblastoma. Proc ASCO. 2007;25(S):9504
  22. Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Paediatric Oncology Group. Eur J Cancer. 1997;33:2121–2125
  23. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. New Engl J Med. 2005;353:2243–2253
  24. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at chromosome 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a children’s cancer study group study. J Clin Oncol. 2000;18:1888–1899
  25. Cheung NK, Kushner BH, LaQuaglia M, et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001;36:227–230
  26. Wolden SL, Gollamudi SV, Kushner BH, et al. Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys. 2000;46:969–974
  27. Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2006;24:2885–2890
  28. Laprie A, Michon J, Hartmann O, et al. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system stage II and III neuroblastoma with MYCN amplification. Cancer. 2004;101:1081–1089
  29. Simon T, Spitz R, Faldum A, Hero B, Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol. 2004;26:791–796
  30. Hero B, Simon T, Spitz R, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26:1504–1510
  31. Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5:1430–1440
  32. Matthay KK, Seeger RC, Reynolds CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children’s Cancer Group. J Clin Oncol. 1994;12:2382–2389
  33. Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumours, and other poor-risk solid tumours in children and young adults. Bone Marrow Transplant. 2001;28:551–556

PII: S0959-8049(08)00748-X

doi: 10.1016/j.ejca.2008.09.016

European Journal of Cancer
Volume 45, Issue 1 , Pages 90-98 , January 2009

Article Tools

* Image Usage & Resolution